---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-23-000034"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:00:52.536563+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve director elections, auditor, and say-on-pay at 2023 annual meeting

## Summary
- Three Class I directors elected: Hindson, Saxonov, Stuelpnagel, each with >88% votes for.
- Ratification of Ernst & Young as independent auditor for FY2023 approved (99.9% votes for).
- Non-binding advisory vote on executive compensation passed with ~82% support (188M for, 39M against).
- Quorum achieved with 85.5% of eligible votes represented (238.3M of 278.8M votes).
- All proposals passed; no broker non-votes on auditor ratification.

## SEC filing metadata
- accession: 0001770787-23-000034
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000034/0001770787-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000034/txg-20230614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-23-000034
- JSON: https://secwatch.observer/filing/0001770787-23-000034.json
- Plain text: https://secwatch.observer/filing/0001770787-23-000034.txt

## Key facts
- Shareholder Votes
  10x Genomics, Inc. shareholders approved Election of three Class I directors at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The Company’s stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company’s 2026 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his or her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000034/0001770787-23-000034-index.htm
- Shareholder Votes
  10x Genomics, Inc. shareholders approved Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers at the 2023-06-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000034/0001770787-23-000034-index.htm
- Shareholder Votes
  10x Genomics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000034/0001770787-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.